Novel Digital Application for Patients With Acute Leukemia

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT06472128
Status
Recruiting
Apply to this trial

Conditions

  • High Risk Acute Myeloid Leukemia
  • Primary Refractory Acute Myeloid Leukemia
  • Relapsed Adult Acute Myeloid Leukemia

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • DREAMLAND — BEHAVIORAL
    Participants assigned to DREAMLAND will start using DREAMLAND during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
  • VITAL WELLNESS — BEHAVIORAL
    Participants assigned to VITAL WELLNESS will start using VITAL WELLNESS during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.

Study Details

This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.

Key Dates

Start date
Oct 21, 2024
Status verified
Nov 2025
Primary completion
Apr 30, 2029
Completion
Apr 30, 2030

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: DREAMLAND
    DREAMLAND is a self-administered, multicomponent mobile psychological intervention application for patients to be used during their hospitalization for intensive chemotherapy.
  • Active Comparator: VITAL WELLNESS
    VITAL WELLNESS is a self-administered, multicomponent mobile application containing information on a range of physical health topics that guide patients through education about general wellness, nutrition, exercise, and cancer prevention.

Primary Outcome Measure

Patient reported quality of life (QOL) at day 20 as measured by the Functional Assessment of Cancer Therapy-Leukemia scale [ Time Frame: Day +20 ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Massachusetts General Hospital (MGH)BostonMassachusetts02114
Areej El-Jawahri, MD
[email protected]
617-724-4000
Upeka Samarakoon, PhD
[email protected]
Duke UniversityDurhamNorth Carolina27710
Thomas W LeBlanc, MD
[email protected]
Fred Hutchinson Cancer Research Center (FHCRC)SeattleWashington98109
Mohamed Sorror, MD
[email protected]

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital (MGH)· Boston, MADuke University· Durham, NCFred Hutchinson Cancer Research Center (FHCRC)· Seattle, WA

Related Studies